Cleavable Linkers for Controlled Drug Release from Solid Supports
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for controlled drug release from solid supports face challenges such as unpredictable release rates due to varying esterase activity across species and individuals, and limitations in crossing cell membranes, especially for extracellular targets, with existing linkers like fluorenylmethoxycarbonyl (Fmoc) systems lacking tunable control.
Innovation Solution
Development of drug-solid support conjugates using cleavable linkers that facilitate controlled beta-elimination reactions at physiological pH, allowing for precise modulation of drug release rates through pH-dependent mechanisms, with protective polymers like PEG providing stability and controlled release from multiple sites on solid supports.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If esterase-catalyzed hydrolysis is used for drug release, then drug release can be achieved, but release rates become unpredictable due to varying esterase activity between species and individuals
Solution Approach 1:
The patent replaces the biological esterase-catalyzed hydrolysis mechanism with a chemical beta-elimination mechanism. This substitution eliminates dependence on variable esterase activity across different species and individuals, providing predictable and controllable drug release rates through inherent chemical stability of the beta-alanine linker at physiological pH.
Solution Approach 2:
The patent modifies the chemical structure of the linker by using beta-alanine derivatives with specific pKa values. By changing the chemical parameters of the linker (such as incorporating electron-withdrawing groups like carboxylic acid or amide), the drug release rate can be precisely tuned and predicted without being influenced by biological variability.
2Reliability
If permanent linkers are used to attach drugs to macromolecules, then pharmaceutical properties are enhanced, but the conjugates cannot cross cell membranes limiting application to extracellular targets only
Solution Approach 1:
The patent creates a dynamic system where the linker transitions from a stable, non-releasable state to a releasable state under specific conditions. The beta-alanine linker remains stable during circulation (maintaining pharmaceutical properties) but becomes cleavable through beta-elimination at the target site, enabling both stable delivery and controlled release for various target types.
Solution Approach 2:
The patent introduces a cleavable beta-alanine linker as an intermediary between the drug and macromolecule. This intermediary maintains the stability needed for circulation while providing a mechanism for controlled release, thereby enabling application to both intracellular and extracellular targets without sacrificing pharmaceutical properties.
3Reliability
If Fmoc or Fms linkers are used for drug attachment, then non-enzymatic beta-elimination release is achieved, but tunable control over release rate is not possible
Solution Approach 1:
The patent systematically modifies the chemical parameters of the beta-alanine linker by incorporating various electron-withdrawing groups (such as carboxylic acid, amide, and ester functionalities) at different positions. These parameter changes directly affect the pKa and beta-elimination rate, enabling precise tuning of drug release kinetics while maintaining conjugate stability during circulation.
Solution Approach 2:
The patent creates composite linker structures combining beta-alanine backbone with various functional groups (carboxylic acid, amide, ester). These composite structures provide both the stability needed for drug-carrier conjugate formation and the tunable beta-elimination properties for controlled drug release, resolving the contradiction between stability and tunability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables predictable and tunable drug release rates, ensuring effective pharmacokinetics and protection from hydrolysis, suitable for various medical applications including implants, stents, and topical applications.
Implementation Method 1
cleavable linkers that release drug through controlled beta elimination reactions
Implementation Method 2
the coupled drug is protected from hydrolysis by the presence of a protective polymer, such as PEG, on different sites at the surface or interstices of the solid support
Data Source
Figure 1
Figure 2~3
Figure 4~5
AI summary
The invention relates to solid supports useful in medical applications that provide controlled release of drugs, such as peptides, nucleic acids and small molecules. The drugs are covalently coupled to the solid support through a linkage that releases the drug or a prodrug through controlled beta elimination.